Metagenomi Therapeutics (MGX) Operating Expenses (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Operating Expenses data on file, last reported at $25.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $25.8 million, down 19.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.1 million (down 13.42% YoY), and the FY2025 annual result was $121.2 million, down 14.15% from the prior year.
• Operating Expenses declined to $25.8 million in Q1 2026 per MGX's latest filing, from $28.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $40.2 million in Q1 2024 and troughed at $25.8 million in Q1 2026.
• A 4-year average of $31.7 million and a median of $31.5 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 51.12% in 2024, then decreased 20.51% in 2025.
• A 4-year view of Operating Expenses shows it stood at $32.6 million in 2023, then slipped by 7.23% to $30.2 million in 2024, then declined by 6.48% to $28.3 million in 2025, then slipped by 8.64% to $25.8 million in 2026.
• Business Quant data shows MGX's Operating Expenses at $25.8 million in Q1 2026, $28.3 million in Q4 2025, and $31.5 million in Q3 2025.